ADMA Biologics Acquires Biotest’s Therapy Business Unit
ADMA Biologics, which develops, manufactures and commercializes specialty plasma-based biologics for the treatment of immune deficiencies and prevention of certain infectious diseases, has acquired Biotest Pharmaceuticals’ Therapy Business Unit.
IVIG Highly Protective in Ferrets After Challenge with Severe Pandemic pH1N1 and Avian H5N1 Influenza Strains
Australian investigators tested the ability of intravenous immune globulin to protect against potential pandemic influenza virus in outbred ferrets, which are naturally susceptible to human influenza viruses and considered a relevant small animal model of human influenza infection.
BCG Vaccine Could Permanently Reverse Type 1 Diabetes
Results of a new clinical trial show that the bacillus Calmette-Guerin vaccine could permanently reverse advanced type 1 diabetes in mice.
Study Shows Influenza May Increase Risk of Developing Parkinson’s
New research suggests a certain strain of influenza virus predisposes mice to developing pathologies that mimic those seen in Parkinson’s disease.
Novo Nordisk’s Rebinyn Approved by FDA to Treat Hemophilia B
The U.S. Food and Drug Administration has approved Novo Nordisk’s Rebinyn (coagulation factorIX [recombinant], glycopegylated) to treat hemophilia B in adults and children.
CDC Study Shows Flu Vaccine Reduces Risk of Death in Children
A new study conducted by the Centers for Disease Control and Prevention shows that during the years 2010 through 2014, the influenza vaccine reduced the risk of flu-associated death by half among children with underlying high-risk medical conditions and by nearly two-thirds among healthy children.
Plasma-Derived Apolipoprotein A-I Infusions Are Well-Tolerated, Acutely Increase Cholesterol Efflux Capacity
Human and recombinant apolipoprotein A-I (apoA-I) is the primary functional component of high-density lipoprotein, and has been shown to increase cholesterol efflux capacity and to regress atherosclerotic disease in animal and clinical studies.
Study Shows Drug to Treat and Prevent Alzheimer ’s Is Safe and Well-Tolerated
A Phase I clinical trial has shown that NGP 555, a drug developed to treat and prevent Alzheimer’s disease, was safe and well-tolerated with dose-dependent plasma exposure.
Flu Vaccine May Cause Immune-Related Adverse Events with Checkpoint Inhibitors
Study results from the division of oncology at University Hospital Basel in Switzerland show that patients treated with PD-1/PD-L1 checkpoint inhibitors may be at an increased risk for adverse events after receiving the seasonal influenza vaccination.
HHS Launches Webpage to Empower Patients
The U.S. Department of Health and Human Services has launched anew page on its website that highlights regulatory and administrative actions it is taking to support a patient-centered healthcare system.
